IL1R1
Interleukin-1 receptor type 1
Also known as: CD121A, D2S1473, IL1R, IL1R1_HUMAN, IL1RA
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P14778
- Gene
- IL1R1
- Ensembl
- ENSG00000115594
- Chromosome
- 2
- Canonical length
- 569 aa
- Protein class
- Cancer-related genes, CD markers, Enzymes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters
- Subcellular location
- Nucleoplasm,Vesicles,Plasma membrane,Cytosol
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes a cytokine receptor that belongs to the interleukin-1 receptor family. The encoded protein is a receptor for interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist. It is an important mediator involved in many cytokine-induced immune and inflammatory responses. This gene is located in a cluster of related cytokine receptor genes on chromosome 2q12. [provided by RefSeq, Dec 2013]
Canonical amino-acid sequenceUniProt
569 residues, UniProt reviewed canonical sequence.
>P14778|IL1R1
1 MKVLLRLICF IALLISSLEA DKCKEREEKI ILVSSANEID VRPCPLNPNE HKGTITWYKD
61 DSKTPVSTEQ ASRIHQHKEK LWFVPAKVED SGHYYCVVRN SSYCLRIKIS AKFVENEPNL
121 CYNAQAIFKQ KLPVAGDGGL VCPYMEFFKN ENNELPKLQW YKDCKPLLLD NIHFSGVKDR
181 LIVMNVAEKH RGNYTCHASY TYLGKQYPIT RVIEFITLEE NKPTRPVIVS PANETMEVDL
241 GSQIQLICNV TGQLSDIAYW KWNGSVIDED DPVLGEDYYS VENPANKRRS TLITVLNISE
301 IESRFYKHPF TCFAKNTHGI DAAYIQLIYP VTNFQKHMIG ICVTLTVIIV CSVFIYKIFK
361 IDIVLWYRDS CYDFLPIKAS DGKTYDAYIL YPKTVGEGST SDCDIFVFKV LPEVLEKQCG
421 YKLFIYGRDD YVGEDIVEVI NENVKKSRRL IIILVRETSG FSWLGGSSEE QIAMYNALVQ
481 DGIKVVLLEL EKIQDYEKMP ESIKFIKQKH GAIRWSGDFT QGPQSAKTRF WKNVRYHMPV
541 QRRSPSSKHQ LLSPATKEKL QREAHVPLGLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IL1R1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 151 nTPM
Expression across tissuesHPA
Tissue
- cervix: 151 nTPM
- adipose tissue: 130 nTPM
- parathyroid gland: 119 nTPM
- placenta: 113 nTPM
- lung: 111 nTPM
- epididymis: 99 nTPM
Single-cell type
- neutrophils: 5,197 nCPM
- endometrial glandular cells: 842 nCPM
- endometrial secretory cells: 776 nCPM
- prostatic glandular cells: 682 nCPM
- endometrial luminal cells: 629 nCPM
- innate lymphoid cells: 365 nCPM
Immune cell
- neutrophil: 1.1 nTPM
- T-reg: 0.5 nTPM
- memory CD4 T-cell: 0.3 nTPM
- basophil: 0.2 nTPM
- MAIT T-cell: 0.2 nTPM
- NK-cell: 0.2 nTPM
Brain region
- medulla oblongata: 25 nTPM
- choroid plexus: 25 nTPM
- thalamus: 23 nTPM
- cerebral cortex: 15 nTPM
- spinal cord: 13 nTPM
- hypothalamus: 11 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IL1R1.
Disease | AllUniProt
Conditions IL1R1 is implicated in, by any mechanism.
- Chronic recurrent multifocal osteomyelitis 3 (CRMO3) MIM:259680
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 59 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Chronic recurrent multifocal osteomyelitis 3
Disease | ImmuneIEDB
Conditions an epitope on IL1R1 was assayed in.
- Lyme disease T cell
ReferencesPubMed · IEDB
Publications for IL1R1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
7 publications
- Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study.
2022 · Lancet Rheumatol · RCR 4.1 · 56 citations - Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease.
2022 · J Allergy Clin Immunol · RCR 2.2 · 26 citations - Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies.
2024 · J Clin Immunol · RCR 2 · 11 citations - IL-1ra ELISA: reduction and alkylation of synovial fluid eliminates interference by IgM rheumatoid factors.
1991 · J Immunol Methods · RCR 1.1 · 43 citations - IL-1RA autoantibodies: insights into mechanisms and associated diseases.
2024 · Am J Transl Res
Reference: B cellIEDB
1 publication
- Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette-Guérin vaccination.
2017 · Int J Infect Dis · RCR 0.7 · 19 citations
Reference: T cellIEDB
1 publication
- Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease.
1999 · Nat Med · RCR 3.3 · 161 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.51
- gnomAD pLI
- 0.15
- gnomAD missense Z
- 1.92
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell surface receptor signaling pathway
- immune response
- inflammatory response
- interleukin-1-mediated signaling pathway
- positive regulation of canonical NF-kappaB signal transduction
- positive regulation of neutrophil extravasation
- positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- positive regulation of platelet-derived growth factor receptor signaling pathway
- positive regulation of T-helper 1 cell cytokine production
- positive regulation of type II interferon production
- regulation of inflammatory response
- response to interleukin-1
- smooth muscle adaptation
- positive regulation of interleukin-1-mediated signaling pathway
Molecular functions
- interleukin-1 binding
- interleukin-1 receptor activity
- interleukin-1, type I, activating receptor activity
- NAD+ nucleosidase activity, cyclic ADP-ribose generating
- platelet-derived growth factor receptor binding
- protease binding
- transmembrane signaling receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Toll/interleukin-1 receptor homology (TIR) domain
- Immunoglobulin domain subtype
- Interleukin-1 receptor type I/II
- Interleukin-1 receptor type 1
- Immunoglobulin-like domain
- Immunoglobulin-like fold
- Interleukin-1 receptor family
- Toll/interleukin-1 receptor homology (TIR) domain superfamily
- Immunoglobulin-like domain superfamily
- IL-1Ra-like, immunoglobulin domain
- TIR domain
- Immunoglobulin domain
- Immunoglobulin domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IL1R1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IL1R1 as an antibody target. Whether an autoantibody or antibody against IL1R1 could matter depends on whether native IL1R1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IL1R1 is annotated at the cell surface, where native IL1R1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label IL1R1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...